Achieve Life Sciences, Inc. (ACHV) Stock Forecast
ACHV analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 4.75 / 5 from 12 analysts
- Price target
- $14.15 average of analyst targets
- Upside to target
- +121.8% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-0.20
- 52-week range
- $2.65 – $8.53
ACHV analyst ratings
12 analystsNumber of analysts at each rating.
ACHV price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
ACHV earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.19 | −$0.36 | −$0.11 | −$0.28 | +30.9% | 12 |
| Current fiscal year (2026) | −$1.38 | −$1.86 | −$0.63 | −$1.25 | −10.4% | 11 |
| Next fiscal year (2027) | −$0.65 | −$1.19 | −$0.14 | −$1.38 | +52.7% | 12 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
ACHV revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 10 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 11 |
| Next fiscal year (2027) | $38.1M | $0 | $119.2M | 0.0% | 12 |
ACHV EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
ACHV revenue: reported and forecast
ACHV EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.16 | −$0.16 | −$0.19 | −$0.19 | −$0.19 | +20.8% | 2 up · 4 down |
| Current fiscal year (2026) | −$0.68 | −$0.68 | −$1.37 | −$1.37 | −$1.38 | +101.6% | 0 up · 0 down |
| Next fiscal year (2027) | −$0.49 | −$0.49 | −$0.64 | −$0.64 | −$0.65 | +32.0% | 2 up · 4 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
ACHV earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; ACHV beat in 6 of 12.
What analysts expect from ACHV
12 analysts cover Achieve Life Sciences; their consensus rating is strong buy (4.75 on a 1–5 scale, where 5 is a strong buy). The average price target is $14.15, 121.8% above the latest close of $6.38. Analysts expect earnings of −$1.38 per share for 2026, −10.4% from a year earlier. For 2027 the average estimate is −$0.65 per share on revenue of $38.1 million. Achieve Life Sciences beat the EPS estimate in 6 of the last 12 quarters.
Related: ACHV income statement, ACHV key metrics, ACHV chart. See the ACHV stock overview for the latest quote and news.
ACHV forecast FAQ
What is Achieve Life Sciences's price target?
The average analyst price target for Achieve Life Sciences is $14.15, 121.8% above the latest close of $6.38.
Is Achieve Life Sciences a buy, hold or sell?
Of 12 analysts covering Achieve Life Sciences, 9 rate it a strong buy, 3 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Achieve Life Sciences's EPS forecast?
Analysts forecast −$1.38 per share for 2026 (range −$1.86 to −$0.63); for 2027 the estimate is −$0.65.
When does Achieve Life Sciences report earnings?
Achieve Life Sciences is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 before the market opens; the EPS estimate is $-0.20.
Does Achieve Life Sciences usually beat earnings estimates?
Achieve Life Sciences reported EPS at or above the analyst estimate in 6 of the last 12 quarters.